Background: Enteral nutrition (EN) is recommended as the preferred route for early nutrition therapy in critically ill adults over parenteral nutrition (PN). A recent large randomized controlled trial (RCT) showed no outcome differences between the two routes. The objective of this systematic review was to evaluate the effect of the route of nutrition (EN versus PN) on clinical outcomes of critically ill patients. Methods: An electronic search from 1980 to 2016 was performed identifying relevant RCTs. Individual trial data were abstracted and methodological quality of included trials scored independently by two reviewers. The primary outcome was overall mortality and secondary outcomes included infectious complications, length of stay (LOS) and mechanical ventilation. Subgroup analyses were performed to examine the treatment effect by dissimilar caloric intakes, year of publication and trial methodology. We performed a test of asymmetry to assess for the presence of publication bias. Results: A total of 18 RCTs studying 3347 patients met inclusion criteria. Median methodological score was 7 (range, 2-12). No effect on overall mortality was found (1.04, 95 % CI 0.82, 1.33, P = 0.75, heterogeneity I 2 = 11 %). EN compared to PN was associated with a significant reduction in infectious complications (RR 0.64, 95 % CI 0.48, 0.87, P = 0.004, I 2 = 47 %). This was more pronounced in the subgroup of RCTs where the PN group received significantly more calories (RR 0.55, 95 % CI 0.37, 0.82, P = 0.003, I 2 = 0 %), while no effect was seen in trials where EN and PN groups had a similar caloric intake (RR 0.94, 95 % CI 0.80, 1.10, P = 0.44, I 2 = 0 %; test for subgroup differences, P = 0.003). Year of publication and methodological quality did not influence these findings; however, a publication bias may be present as the test of asymmetry was significant (P = 0.003). EN was associated with significant reduction in ICU LOS (weighted mean difference [WMD] -0.80, 95 % CI −1.23, −0.37, P = 0.0003, I 2 = 0 %) while no significant differences in hospital LOS and mechanical ventilation were observed. Conclusions: In critically ill patients, the use of EN as compared to PN has no effect on overall mortality but decreases infectious complications and ICU LOS. This may be explained by the benefit of reduced macronutrient intake rather than the enteral route itself.
Background
Artificial nutrition support has evolved into a primary therapeutic intervention to prevent metabolic deterioration and loss of lean body mass with the aim to improve the outcome of critically ill patients. Apart from the timing of initiation and the targeted amount of macronutrients, the route of delivery is viewed as an important determinant of the effect of the nutritional intervention. Using the enteral route is considered to be more physiologic, providing nutritional and various non-nutritional benefits including maintenance of structural and functional gut integrity as well as preserving intestinal microbial diversity [1] [2] [3] . The disadvantage of enteral nutrition (EN) is related to a potential lower nutritional adequacy particularly in the acute disease phase and in the presence of gastrointestinal dysfunction [4, 5] . In contrast, parenteral nutrition (PN) may better secure the intended nutritional intake but is associated with more infectious complications, most likely due to hyperalimentation and hyperglycemia, as consistently shown in earlier meta-analyses [6] [7] [8] [9] . These clinical data have translated into widespread consensus among current international guideline recommendations [10] [11] [12] [13] and expert opinions [14, 15] that the enteral route is preferred in critically ill patients without a contraindication to EN.
Recently, Harvey and coworkers conducted the largest randomized controlled trial (RCT) to date with respect to the effect of the route of nutrition on the outcome of critically ill adult patients [16] . In this pragmatic RCT involving 2388 patients, neither a significant difference in mortality nor infectious complications was found between the patients receiving total PN or EN within 36 hours after admission and up to a maximum of 5 days. These results have challenged the paradigm that EN is superior to PN with regard to clinical outcomes in critical illness.
Therefore, the objective of this study was to perform an updated systematic literature review and metaanalysis of this topic to evaluate the overall effect of the route of nutrition (EN versus PN) on clinical outcomes in adult critically ill patients.
Methods

Search strategy and study identification
A literature review was conducted to identify all relevant RCTs published between 1980 and January 2016 in MEDLINE, Embase, CINAHL, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews. The following keywords or medical subject headings were used: "randomized", "clinical trial", "nutrition support", "artificial feeding", "enteral nutrition", "parenteral nutrition", "intensive care", "critical illness", and "critically ill". The literature search was not confined to articles written only in English. The authors' personal files and reference lists of relevant review articles were also reviewed. Neither ethics board approval nor patient consent was required due to the nature of a systematic review.
Study eligibility criteria
Trials were included only if they met the following characteristics:
1. Type of study: RCT with a parallel group. 2. Population: critically ill adult patients (≥18 years of age), defined as patients admitted to an intensive care unit (ICU). In the event that the information on the study population was unclear, we considered a mortality rate higher than 5 % in the control group to be consistent with critical illness. We excluded RCTs performed in elective surgery patients (such as cardiac surgery patients) even if patients were cared for in an ICU in the postoperative period. 3. Intervention: enteral versus parenteral nutrition 4. Trial outcomes: the trial reported clinically relevant outcomes. Overall mortality was the primary outcome for this meta-analysis. Where available, we extracted data regarding the primary mortality outcome reported as the principal outcome of the study, including ICU, hospital, 28-day mortality or other. Secondary outcomes were infections, ICU and hospital length of stay (LOS), and duration of mechanical ventilation with definitions of infections as defined in the original articles. As in previous metaanalyses conducted by our group, we excluded those trials that reported only nutritional, biochemical, metabolic, or immunologic outcomes.
Data abstraction
The methodological quality of the included trials was assessed in duplicate by two independent reviewers using a data abstraction form with a scoring system from 0 to 14 according to the following criteria as previously described [8, 17] :
(a) the extent to which randomization was concealed, (b) blinding, (c) analysis based on the intention-to-treat (ITT) principle, (d) comparability of groups at baseline, (e) extent of follow-up, (f ) description of treatment protocol, (g) co-interventions, (h) definition of clinical outcomes.
Disagreement concerning the individual score of each of the defined categories was resolved by consensus between the two reviewers. Moreover, attempts were made to contact the authors of the included trials in order to request further information not contained in the published article, if needed.
Statistical analysis
Statistical analyses were performed using RevMan 5.3 (Cochrane IMS, Oxford, UK) with a random effects model. All trial data were combined to estimate the pooled risk ratio (RR) with 95 % confidence intervals (CIs) for mortality and infections and overall weighted mean difference (WMD) with 95 % confidence intervals for LOS and mechanical ventilation data. We calculated pooled RRs using the Mantel-Haenszel estimator, and WMDs were estimated by the inverse variance approach. The random effects model of DerSimonian and Laird was applied to estimate variances for the MantelHaenszel and inverse variance estimators [18] . In case RRs were undefined they were excluded for studies with no event in either arm. Heterogeneity testing was performed using a weighted Mantel-Haenszel χ 2 test and quantified by the heterogeneity I 2 statistic as implemented in RevMan. Differences between subgroups were analyzed using the test of subgroup differences described by Deeks et al. [19] , and the results expressed using the P values.
Generating funnel plots and testing asymmetry of outcomes using the method proposed by Rücker et al. [20] addressed possible publication bias. We considered P < 0.05 to be statistically significant.
Subgroup analyses
A predefined subgroup analysis was performed to further explore whether the treatment effect of either route is associated with significant differences in the caloric intake across the study groups (EN compared to PN). A priori, we hypothesized that a possible negative treatment effect of PN on mortality, infectious complications and length of stay is related to a higher caloric intake. We used the reported significance level on caloric intake across groups from each study to determine the allocation to the subgroup. We also assessed the effect of trial publication date and trial quality on the outcome based on the hypothesis that older or methodologically weaker studies tended to yield a more negative treatment effect of PN. For this purpose, we designated trials with a publication date later than 1995 (median year 1994-1995) as newer and trials with a methodological score of more than 7 (median score) as methodologically stronger, respectively. In addition, we conducted a sensitivity analysis excluding two studies [21, 22] we were uncertain if the patients were truly critically ill [21] and about the trial results [22] and authors did not respond to attempts to obtain clarification.
Results
Study identification and selection
The literature search identified 83 potentially eligible randomized controlled trials, of which 65 were excluded for the following reasons (see Table A1 in Additional file 1): (a) patients not considered to be adult critically ill patients (N = 42), (b) no relevant clinical outcomes meeting inclusion criteria reported (N = 4), (c) being duplicate studies, reviews of published trials or subgroups of included studies (N = 11), (d) non-randomized or pseudo-randomized study design (N = 7), and/or (e) control group received a nonstandard enteral formula (N = 1).
Thus, 18 RCTs with a total number of 3347 critically ill adult patients were finally included in the metaanalysis, whereof 1681 patients were treated with EN and 1666 patients with PN.
The median methodological score of the included 18 RCTs was 7 (range, 2-12) of which 10 RCTs were rated with a score ≤7 and 8 RCTs with a score >7. The median year of publication was 1994-1995 with 10 RCTs published before or in 1995 and 8 RCTs after 1995. All results were based on the individual trial data shown in Tables 1 and 2 .
Effect of EN versus PN on mortality
Aggregating data from all studies reporting on mortality (N = 16) there was no difference in overall mortality between the groups receiving EN or PN (RR 1.04, 95 % CI 0.82, 1.33, P = 0.75, heterogeneity I 2 = 11 %) (Fig. 1) . In the subgroup analysis where trials were aggregated according to the caloric intake across groups, no effect on mortality was seen in trials (N = 4) where the PN group received significantly more calories than the EN group (RR 1.58, 95 % CI 0.75, 3.35, P = 0.23, heterogeneity I 2 = 48 %) or in the nine trials where the caloric intake was reported to be non-significantly different across groups (RR 1.03, 95 % CI 0.93, 1.14, P = 0.55, heterogeneity I 2 = 0 %; test for subgroup differences: P = 0.55) (Fig. 1, Panels a and b) . Three RCTs did not report the caloric intake across study groups (Fig. 1,  Panel c) . In the sensitivity analysis excluding two studies [21, 22] , there was still no difference in mortality between groups (RR 1.08, 95 % CI 0.83, 1.39, P = 0.57, heterogeneity I 2 = 14 %).
Effect of EN versus PN on infectious complications
Eleven trials were aggregated which reported on infectious complications. EN compared to PN was associated with a significant reduction in the incidence of infectious complications (RR 0.64, 95 % CI 0.48, 0.87, P = 0.004, heterogeneity I 2 = 47 %; Fig. 2 ). The significant difference was also seen in the subgroup analysis of five aggregated trials in which the PN group had a significantly higher caloric intake than the EN group (RR 0.55, 95 % CI 0.37, 0.82, P = 0.003, heterogeneity I 2 = 0 %) but not when the five trials were aggregated where caloric intake was similar between EN and PN groups (RR 0.94, 95 % CI 0.80, 1,10, P = 0.44, heterogeneity I 2 = 0 % [test for subgroup differences: P = 0.003]) (Fig. 2 , Panels a and b). One trial with data on infectious complications did not report the caloric intake across the EN and PN group (Fig. 2 , Panel c). EN compared to PN was still associated with a significant reduction in infectious complications (RR 0.58, 95 % CI 0.41, 0.8, P = 0.001, heterogeneity I 2 = 29 %) in the sensitivity analysis excluding the two studies with inconclusive status of critical illness [21, 22] .
Effect of EN versus PN on ICU and hospital length of stay
Only four studies reported on ICU LOS (in mean and standard deviation [SD] ) and when the data were aggregated, the use of EN was associated with a significant reduction in ICU LOS (WMD −0.80, 95 % CI −1.23, −0.37, P = 0.0003, heterogeneity I 2 = 0 %, Fig. 3 , Panel a). In the subgroup analysis aggregating trials according to the caloric intake across groups, the significant difference was not observed in the two trials where caloric intake was similar between EN and PN groups (RR −0.47, 95 % CI −2.23, 
Effect of EN versus PN on mechanical ventilation
A total of four RCTs reported on length of mechanical ventilation (in mean and standard deviation) with no overall effect observed (WMD −0.38, 95 % CI −0.98, 0.21, P = 0.21, heterogeneity I 2 = 0 %, Fig. 3 , Panel c).
Effect of trial quality and publication date on outcomes and risk of publication bias
According to the subgroup analyses, there was no effect of either route of nutrition on overall mortality in highquality trials (N = 7 RCTs; RR 1.05, 95 % CI 0.94, 1.16; P = 0.38, heterogeneity I 2 = 0 %) compared to low-quality trials (N = 9 RCTs; RR 1.00, 95 % CI 0.62, 1.60; P = 1.00, heterogeneity I 2 = 30 %; test for subgroup differences: P = 0.85). This also applied to the comparison of older (N = 8 RCTS ≤ 1995; RR 1.01, 95 % CI 0.56, 1.83; P = 0.98, heterogeneity I 2 = 33 %) versus more recent publications (N = 8 RCTs > year 1995; Patients randomized to a third intervention group (combined enteral and parenteral nutrition) of the concerned trial were excluded from this meta-analysis created to further test for potential publication bias. The test for asymmetry was found to be significant for the reported endpoint infectious complications (P = 0.003) (Fig. 4) . No significant differences were found with respect to the remaining endpoints of overall mortality (P = 0.61), ICU LOS (P = 0.34), hospital LOS (P = 0.30) or mechanical ventilation (P = 0.65) (data not shown).
Discussion
This updated meta-analysis on the effect of the route of nutrition (EN versus PN) on clinical outcomes included 18 randomized controlled trials with a total of 3347 randomized critically ill adult patients. Overall, there was no difference in mortality between the two routes of nutrition. EN as compared to PN led to a significant reduction in the number of infectious complications and ICU LOS while no significant effect was found with respect to hospital LOS and mechanical ventilation. However, the positive treatment effect of EN on infectious morbidity and ICU LOS may be attributed to differences in caloric intake between study groups. Furthermore, funnel plot analysis revealed evidence for significant publication bias for the trials reporting on infectious complications.
Comparison to other meta-analyses
Six previous meta-analyses comparing the effect of EN versus PN on clinical outcomes of critically ill adults reported no significant overall difference in mortality between the two routes of nutrition [6, 7, 9, [23] [24] [25] . The meta-analysis by Simpson and Doig [25] including 11 RCTs only showed a mortality benefit of PN in a predefined subgroup analysis where PN was compared to delayed EN (odds ratio [OR] 0.29, 95 % CI 0.12, 0.70, P = 0.006; heterogeneity I 2 = 0 %, statistical heterogeneity P = 0.60). In the absence of an overall mortality effect, all of these meta-analyses showed significant reductions in the rate of infectious complications with the use of EN and one meta-analysis also showing a significant reduction of hospital LOS (WMD = 1.20 days; 95 % CI 0.38, 2.03; P = 0.004) [9] .
In contrast to these previous meta-analyses, our updated results include the data of the recent multicenter RCT ("Calories trial") by Harvey and coworkers [16] . In this pragmatic trial including 2400 critically ill patients, the use of total PN was compared with EN for a duration of 5 days after ICU admission. The calorie and protein intake was similar, albeit low with respect to the predefined nutrition target in both groups, while initiation of oral feeding was allowed if clinically indicated during the intervention period. Neither were there significant differences in the 90-day mortality primary endpoint nor in the rate of infectious complications or other secondary outcome measures including LOS variables and duration of mechanical ventilation. Why the increased infectious morbidity seen with PN in the former trials and meta-analyses was not observed in this latest largest RCT may have been related to the equally hypocaloric delivery of macronutrients via both routes.
Effect of dissimilar caloric intake
In contrast to the results of the Calories trial [16] , the overall significant positive treatment effect of EN on infectious morbidity and ICU LOS remained in our updated meta-analysis. On the one hand, this overall treatment effect may reflect the positive non-nutritional effects of EN in terms of preservation of gut integrity and intestinal microbial diversity as well as promotion of gut-mediated immunity, all of which may support the systemic immune response [2, 26] . Presumably, the duration of the intervention (5 days) in the Calories trial [16] was likely too short or not intense enough in a population with a mortality rate of 34 % that the beneficial non-nutritional, trophic effects of EN became evident with respect to infectious morbidity and ICU LOS. On the other hand, our subgroup findings support the hypothesis that not the route per se but rather likely the dissimilar amount of calories delivered may have influenced the treatment effect on infectious complications. While there was a significant treatment effect difference in the subgroup of five RCTs where caloric intake was reported to be significantly higher in the PN group, no treatment effect on infectious complications was observed in the five trials with similar caloric intake across the study groups. This latter subgroup observation was largely driven by the Calories trial contributing 23.8 % of the overall estimate [16] . Furthermore, studies showing differences in infectious complications were associated with publication bias. Except for one RCT [27] , the caloric intake in the PN group was gradually increased to target in all aggregated trials. Still, PN as compared to EN poses a higher risk of providing macronutrients in excess of the metabolic capacity, particularly in the early phase of illness and in the absence of appropriate metabolic control [28] . Caloric overfeeding per se is regarded to negatively influence outcomes with an increased risk of infectious complications while a restricted delivery of macronutrients or the avoidance of overfeeding may preserve autophagy and thus likely positively influence outcome [29, 30] . Unfortunately, owing to the limited number of trials in which the relation of nutritional intakes and predefined targets were reported, we were neither able to further explore the treatment effect of nutritional adequacy nor hyperglycemia on infectious complications in more detail. With respect to the effect of EN-specific complications such as vomiting, aspiration or diarrhea on clinical outcomes, we were unable to complete another subgroup analysis due to inconsistent reporting in the included RCTs. The Calories trial revealed that PN as compared to EN was associated with a lower rate of vomiting and diarrhea but a higher rate of constipation [16] . However, the impact of EN-specific complications remains inconclusive given the non-significant differences in major clinical outcomes in the Calories trial and two other large RCTs comparing the effect of different EN feeding strategies [31, 32] .
Effect of trial quality and publication bias
Most of the RCTs that were aggregated in our metaanalysis were single-center trials reporting small total number of patients, and ten RCTs were published more than 20 years ago. Based on the hypothesis that older or methodologically weaker studies per se tended to yield the more negative treatment effect of PN, we performed additional subgroup analyses as well as funnel plots to assess risk of publication bias. In the early meta-analysis by Braunschweig et al., the positive treatment effect of EN compared to PN on infection rates was independent of the publication date and trial quality score [6] . While the positive treatment effect of EN on infectious morbidity accordingly appeared to be independent of the publication date and methodological trial quality in our metaanalysis, the funnel plot analysis revealed significant asymmetry with respect to infectious complication rates. This bias is apparently driven by the published smaller trials showing a larger treatment effect weakening the strength of the inference we can make about the overall effect of the route of nutrition on infectious complication rates.
Strength and limitations
The strengths of our meta-analysis are the comprehensive and most up-to-date search of the worldwide literature without restriction to only English-written articles, the inclusion of data from the largest and most recent RCT by Harvey and coworkers [16] , the duplicate data abstraction and specific criteria for searching and analysis, and the analysis of trial quality, publication year, and publication bias. Limitations of our meta-analysis include the missing outcome data points in some of the included trials, and the small number of aggregated trials with data on the clinical endpoints ICU LOS and duration of mechanical ventilation. Further limitations are the variation in reporting the caloric intake, the time of nutrition intervention, and the definitions used for infections with or without adjudication across the trials included in the subgroup analysis. We were also unable to separate the effect of protein intake via both routes on the reported clinical endpoints among the included trials. Thus, there may be other covariates driving the observed findings that were not adjusted for in our meta-analysis. This may also pertain to possible treatment effect differences of EN versus PN among specific subpopulations of critically ill patients, such as those with a different nutritional risk upon ICU admission.
The results of our meta-analysis may not be applicable to patients with a relative short-term or absolute contraindication for EN where the treatment effect of PN (as compared to standard care or no nutrition) on clinical outcomes may differ, as shown in two recent large RCTs [33, 34] . Moreover, the effect on long-term functional outcomes were not studied in the aggregated RCTs but are currently viewed as the more appropriate endpoints to be influenced by different nutritional interventions including the route and amount of nutrition [14, 35] . Lastly, we did not examine cost-effectiveness of the two strategies of nutrition due to the inconsistency of reported data in the trials. It is likely that EN will incur less cost as compared to PN as shown by a secondary analysis of the Calories trial [36] .
Conclusions
In this comprehensive and most up-to-date systematic review we found that the route of nutrition (EN versus PN) does not impact mortality in a heterogeneous population of critically ill adult patients. Overall, the use of EN as compared to PN significantly reduced the rate of infectious complications and length of ICU stay. However, the different treatment effect concerning infectious morbidity favouring EN must be interpreted in light of the observed differences in caloric intake across study groups and publication bias of included trials. Although these observations reduce the strength of inference with respect to the negative effects of PN on infectious morbidity, the observed favourable effects of EN on ICU LOS, the ease of access, and lower costs in patients who tolerate EN should be considered. Therefore, in accordance with the most recent guideline recommendations [11, 12] , we posit that EN still should be considered the first-line nutritional therapy in adult critically ill patients with a functioning gastrointestinal tract.
Key messages
This updated meta-analysis on effects of EN versus PN on clinical outcomes included 18 RCTs with 3347 randomized critically ill patients There was no significant difference in mortality between patients fed via EN or PN Compared to PN, the use of EN was associated with a significant reduction of infectious complications and ICU LOS This positive treatment effect of EN compared to PN may be attributed to differences in caloric intake and significant publication bias among aggregated trials EN still should be considered first-line nutritional therapy over PN in critically ill patients with a functioning gastrointestinal tract
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